CVR number 42134015
Industry 72.1100 Research and experimental development on biotechnology

Epitopia ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2022/5
2022
2023/5
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 11.5% 28.8% 19.2%  
Credit score (0-100)  0 0 20 1 6  
Credit rating  N/A N/A BB B B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2022/5
2022
2023/5
2023
2023/12
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -8.4 -26.4 -11.3  
EBITDA  0.0 0.0 -8.4 -26.4 -11.3  
EBIT  0.0 0.0 -8.4 -26.4 -11.3  
Pre-tax profit (PTP)  0.0 0.0 26.8 4.1 -12.7  
Net earnings  0.0 0.0 20.9 3.2 -9.9  
Pre-tax profit without non-rec. items  0.0 0.0 26.8 4.1 -12.7  
 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2022/5
2022
2023/5
2023
2023/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 61.3 64.5 54.6  
Interest-bearing liabilities  0.0 0.0 50.0 67.4 88.6  
Balance sheet total (assets)  0.0 0.0 758 164 158  
Net Debt  0.0 0.0 -612 -89.5 -62.1  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2022/5
2022
2023/5
2023
2023/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -8.4 -26.4 -11.3  
Gross profit growth  0.0% 0.0% 0.0% -214.2% 57.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 758 164 158  
Balance sheet change%  0.0% 0.0% 0.0% -78.4% -3.3%  
Added value  0.0 0.0 -8.4 -26.4 -11.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 -2.0 -3.0  

Profitability 
2019
N/A
2020
N/A
2021
2022/5
2022
2023/5
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 3.6% 0.9% -6.7%  
ROI %  0.0% 0.0% 24.3% 3.4% -7.9%  
ROE %  0.0% 0.0% 34.1% 5.0% -16.7%  

Solidity 
2019
N/A
2020
N/A
2021
2022/5
2022
2023/5
2023
2023/12
Equity ratio %  0.0% 0.0% 8.1% 39.4% 34.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 7,286.7% 339.5% 547.1%  
Gearing %  0.0% 0.0% 81.5% 104.5% 162.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 1.1% 0.2% 2.4%  

Liquidity 
2019
N/A
2020
N/A
2021
2022/5
2022
2023/5
2023
2023/12
Quick Ratio  0.0 0.0 1.1 1.7 1.5  
Current Ratio  0.0 0.0 1.1 1.7 1.5  
Cash and cash equivalent  0.0 0.0 661.7 157.0 150.7  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2022/5
2022
2023/5
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 61.3 64.5 54.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2022/5
2022
2023/5
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0